UPMC Enterprises Invests in RAAPID to Expand AI Risk Adjustment Platform

RAAPID, Inc. just locked in a Series A led by M12, Microsoft’s venture fund, and this one lands a little different if you’ve ever stared down a stack of charts that don’t agree with each other. This isn’t hype capital. This is capital that expects receipts.

Credit where it’s due. Chetan Parikh, Founder and CEO, and Vatsal Ghiya, Co-Founder & CMO, didn’t build another AI that guesses loudly and hopes compliance doesn’t notice. They built something that understands the quiet parts of healthcare data. The messy notes, the buried diagnoses, the stuff that usually gets lost between a physician’s pen and a payer’s spreadsheet. Neuro symbolic AI sounds like a mouthful until you realize it’s just code learning how to think like a clinician instead of a calculator.

M12 doesn’t show up for science projects. They show up when infrastructure is about to matter. And risk adjustment is infrastructure. Billions ride on getting it right, and even more get lost when it’s wrong. RAAPID steps into that chaos with a platform that doesn’t just surface conditions, it backs them up with defensible, audit-ready logic. Translation for the operators in the room. Faster chart reviews, tighter coding accuracy, and outcomes that don’t fall apart the second someone says “prove it.”

The round also pulled in UPMC Enterprises, which tells you this isn’t just capital, it’s proximity to real healthcare systems that live and breathe this problem every day. That combination matters. Capital gives you runway. Strategic investors give you friction, and friction is where good products either sharpen up or tap out.

There’s a lesson sitting under all of this. RAAPID didn’t win because AI is hot. Everyone has AI in their deck. They won because they picked a painful, regulated, detail obsessed corner of healthcare and decided to be unreasonably precise. While others were busy being impressive, they focused on being correct. Turns out, in healthcare, correct scales better than impressive.

And if you’re a payer or provider trying to make sense of risk in a system that rarely makes sense back, this is the kind of tooling that doesn’t just optimize workflows. It changes the conversation from “what did we miss” to “what can we prove.”